Joel Liederman, MaRS Innovation’s vice-president of Business Development and Physical Sciences, was quoted in a National Post article, published August 13, probing whether Canadian research is passing the commercialization test.
Here's an excerpt:
While academics have often been accused of being disconnected from the real world and consuming themselves with the theoretical, it’s hard to imagine they would be able to get away with squandering funding dollars on things that make them go hmmm, particularly in light of the hyper focus on fiscal ...
Olympians from all over the world are gathering today in London, England for the Opening Ceremony of the Games of the XXX Olympiad.
For the thousands of athletes set to enter the stadium behind their countries’ flags, the Olympics represent the pinnacle of their athletic careers.
But the two-week competition will also be the beginning of a legacy that continues throughout their lives, returning to touch them in ways both expected and surprising.
Just ask Jackie Terry.
Terry, MaRS Innovation’s program administrator for the Proof ...
Xagenic, a MaRS Innovation spin-off company, was featured in the most recent issue of BioCentury.
Here's an excerpt (the article only available to BioCentury subscribers):
PCR-based diagnosis of infections can delay treatment decisions by days or hours because the method relies on technical expertise and equipment not available in most point-of-care settings. Xagenic Inc.'s chip-based arrays use a non-PCR, electrochemical approach to diagnose bacterial infections at the point of care in 20 minutes with PCR-like accuracy.
Xagenic's core technology is a silicon chip containing ...
The Los Angeles Times featured Dr. Gregory Czarnota's research in their Science Now section on July 10, 2012, which reports on discoveries from the world of science and medicine (update: the article is no longer available online).
Czarnota, a researcher at the Sunnybrook Health Sciences Centre, is working with MaRS Innovation to license his patented technology: radiosensitization of tumour cells using a combination of microbubbles and targeted, high-intensity, focused ultrasound. (more…)
Xagenic’s financing round to test platform and first diagnostic assay, continue product development and begin FDA submission
Toronto, ON (December 2, 2013) — MaRS Innovation’s first start-up company, Xagenic Inc., is developing the first lab-free molecular diagnostic platform with a 20-minute time-to-result based on University of Toronto research by Professors Shana Kelley and Edward Sargent.
Today, Xagenic announced it has successfully closed a Series B financing round totaling $20 million. New investor Domain Associates, LLC, led the round, joined by existing investors who ...
MaRS Innovation's President and CEO, Raphael Hofstein, has published an editorial outlining the challenges facing entrepreneurs seeking to bring new healthcare innovations to market for the National Post's Medical Devices supplement.
The article, titled "Investing in innovation for a healthier Canada," is available on page 2 of the Post supplement.
Posted by Elizabeth Monier-Williams, marketing and communications officer.
Joel Liederman, MaRS Innovation's vice-president of Business Development and Physical Sciences, is participating in a live chat on the Financial Post's website.
The chat will take place on June 28, 2012 at 2 pm.
Topic: Why Canada can't do anything with its big ideas
When it comes to academic research and the development or discovery of new concepts or product models, there are few countries in the world that can hold a candle to Canada. (more…)
U.K. Trade and Investment (UKTI) has posted a Youtube video featuring Canadian companies looking to expand their operations to Britain.
Flybits, a Mars Innovation spin-off company, was among three companies to be profiled:
Flybits is launching a corporate presence in East London's Tech City, which is also known as the Silicon Roundabout. (more…)
This week, MaRS Innovation (MI) announced a new partnership agreement with The Québec Consortium for Drug Discovery (CQDM), the Ontario Brain Institute (OBI) and Ontario Centres of Excellence (OCE) to launch the Québec/Ontario CQDM Funding Program.
The funding program will support collaborative life science research projects between the two provinces that seek to develop new tools for biopharmaceutical research. (more…)